Responses of rat substantia nigra compacta neurones to L‐DOPA
暂无分享,去创建一个
[1] P. Calabresi,et al. The mechanism of amphetamine‐induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording in vitro , 1989, British journal of pharmacology.
[2] P. Calabresi,et al. Physiology and pharmacology of dopamine D2‐receptors , 1989, Neurology.
[3] N. Mercuri,et al. Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[4] J. Woodward,et al. Calcium-dependent and -independent release of endogenous dopamine from rat striatal synaptosomes , 1988, Brain Research.
[5] W R Woodward,et al. Does an inhibitory action of levodopa contribute to motor fluctuations? , 1988, Neurology.
[6] P. Calabresi,et al. Endogenous dopamine and dopaminergic agonists modulate synaptic excitation in neostriatum: Intracellular studies from naive and catecholamine-depleted rats , 1988, Neuroscience.
[7] N. Mercuri,et al. On the potassium conductance increase activated by GABAB and dopamine D2 receptors in rat substantia nigra neurones. , 1988, The Journal of physiology.
[8] G. Robertson,et al. Evidence that the substantia nigra is a site of action for l-DOPA , 1988, Neuroscience Letters.
[9] L. Cubeddu,et al. Sustained high release at rapid stimulation rates and reduced functional autoreceptors characterize prefrontal cortex dopamine terminals. , 1988, The Journal of pharmacology and experimental therapeutics.
[10] N. Mercuri,et al. Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. , 1987, The Journal of physiology.
[11] T. Chase,et al. Levodopa methyl ester treatment of Parkinson's disease , 1987, Neurology.
[12] U. Ungerstedt,et al. Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis , 1986, Brain Research.
[13] J. Woodward,et al. Correlation of rates of calcium entry and endogenous dopamine release in mouse striatal synaptosomes , 1985, Brain Research.
[14] E. Melamed,et al. Suppression of L‐dopa‐induced circling in rats with nigral lesions by blockade of central dopa‐decarboxylase , 1984, Neurology.
[15] R. Pinnock. The actions of antipsychotic drugs on dopamine receptors in the rat substantia nigra , 1984, British journal of pharmacology.
[16] R. Pinnock. Sensitivity of compacta neurones in the rat substantia nigra slice to dopamine agonists. , 1983, European journal of pharmacology.
[17] G. Rinaldi,et al. Does acutel-DOPA increase active release of dopamine from dopaminergic neurons? , 1983, Brain Research.
[18] E. Melamed,et al. Dopamine release in rat striatum after administration ofl-DOPA as studied with in vivo electrochemistry , 1981, Brain Research.
[19] J. Glowinski,et al. Dendritic release of dopamine in the substantia nigra , 1981, Nature.
[20] R. Wurtman,et al. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease , 1980, Nature.
[21] J. Glowinski,et al. Release of dopamine in vivo from cat substantia nigra , 1977, Nature.
[22] T. Jessell,et al. Release of dopamine from dendrites in rat substantia nigra , 1976, Nature.
[23] J. Korf,et al. Dopamine release in substantia nigra? , 1976, Nature.
[24] O. Hornykiewicz. The mechanisms of action of L-dopa in Parkinson's disease. , 1974, Life sciences.
[25] R. Roth,et al. Comparison of effects of L-dopa, amphetamine and apomorphine on firing rate of rat dopaminergic neurones. , 1973, Nature: New biology.
[26] B. Bunney,et al. CENTRAL DOPAMINERGIC NEURONS: NEUROPHYSIOLOGICAL IDENTIFICATION AND RESPONSES TO DRUGS* , 1973 .
[27] T. Chase,et al. L-Dopa-Induced Release of Cerebral Monoamines , 1970, Science.
[28] George C. Cotzias,et al. Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.
[29] O. Hornykiewicz. Dopamine (3-hydroxytyramine) and brain function. , 1966, Pharmacological reviews.
[30] A. Barbeau. The use of L-DOPA in Parkinson's disease: a 20 year follow-up , 1981 .